Medical Director, Clinical Development
Denali Therapeutics
Summary
To support our growing pipeline, we are seeking a Medical Director, Clinical Development, to provide clinical leadership for our enzyme replacement programs. The ideal candidate will have experience in neurology or rare disease drug development, including the execution of therapeutic clinical trials.
Job description
The Medical Director will report to the Executive Director, within Clinical Development, and will play a critical role in shaping clinical strategy, collaborating cross-functionally, and engaging with external experts, investigators, and study sites.
This is an exciting opportunity for a physician/physician-scientist with a strong background in neurology and clinical development to help advance innovative therapies for patients.
Key Accountabilities / Core Job Responsibilities:
- Provide clinical leadership on one or more programs, including the development and execution of Clinical Development Plans (CDPs).
- Oversee clinical science aspects of trial design, execution, interpretation, and reporting, with a focus on safety, pharmacodynamics, and efficacy.
- Collaborate cross-functionally with translational, regulatory, statistical, clinical operations, and safety teams to ensure integrated, data-driven development plans.
- Lead the creation of clinical documents, including study protocols, investigator brochures, clinical study reports, and regulatory submissions.
- Conduct and supervise medical monitoring and safety reporting throughout trials.
- Provide medical oversight for adverse event (AE) and serious adverse event (SAE) assessments and follow-up.
- Mentor clinical science team members.
- Interacts with external clinical experts, investigators, and advisory boards to support clinical and translational development.
- Represent Denali and its programs in both internal and external forums.
- Champion a culture of compliance, ethics, patient-centricity, and scientific rigor.
Qualifications/Skills:
- MD or MD-PhD; formal training in neurology is strongly preferred. Subspecialty experience in pediatric neurology, immunology, or genetics is ideal.
- Minimum of 3+ years of post-training clinical development experience in industry or equivalent clinical or academic research experience, preferably in neurology.
- Proven ability to lead cross-functional teams in a biopharmaceutical environment.
- Demonstrated experience in therapeutic trial planning and execution for neurological indications, including FIH and other clinical studies.
- Strong understanding of biomarker-driven strategies and medical monitoring.
- Effective cross-disciplinary collaboration skills.
- Excellent written and verbal communication skills, with strong presentation capabilities.
- Growth mindset.
Requirements
- MD or MD-PhD
- Formal training in neurology strongly preferred
- Subspecialty experience in pediatric neurology, immunology, or genetics ideal
- Minimum of 3+ years of post-training clinical development experience in industry or equivalent clinical or academic research experience, preferably in neurology
- Proven ability to lead cross-functional teams in a biopharmaceutical environment
- Demonstrated experience in therapeutic trial planning and execution for neurological indications, including FIH and other clinical studies
- Strong understanding of biomarker-driven strategies and medical monitoring
- Effective cross-disciplinary collaboration skills
- Excellent written and verbal communication skills, with strong presentation capabilities
- Growth mindset
Benefits
- 401(k)
- Healthcare coverage
- ESPP
Company overview
Denali Therapeutics is a pioneering biotechnology company focused on developing innovative therapeutics for neurodegenerative and lysosomal storage diseases. Founded in 2015 and headquartered in South San Francisco, California, the company has developed a proprietary TransportVehicle™ (TV) platform designed to enable biotherapeutics to cross the blood-brain barrier, addressing one of the most significant challenges in treating central nervous system disorders. Denali's pipeline includes promising candidates for conditions such as Hunter syndrome (MPS II), Parkinson's disease, frontotemporal dementia, Sanfilippo syndrome (MPS IIIA), and MPS I, with several programs in advanced clinical development stages. The company collaborates with major pharmaceutical partners including Biogen and Sanofi, leveraging its platform technology to create a new class of barrier-crossing therapeutics. With approximately 500-1,000 employees and operations spanning multiple locations including Salt Lake City, Denali Therapeutics represents a leading force in neuroscience drug development, combining deep scientific expertise with a patient-centric approach to transform treatment paradigms for serious neurological conditions.